Sinn, M., Sinn, B. V., Treue, D., Keilholz, U., Damm, F., Schmuck, R., . . . Denkert, C. (2020). TP53 mutations predict sensitivity to adjuvant gemcitabine in patients with pancreatic ductal adenocarcinoma: Next-generation sequencing results from the CONKO-001 trial. Clinical cancer research, 26(14), . https://doi.org/10.1158/1078-0432.CCR-19-3034
Chicago-Zitierstil (17. Ausg.)Sinn, Marianne, et al. "TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-generation Sequencing Results from the CONKO-001 Trial." Clinical Cancer Research 26, no. 14 (2020). https://doi.org/10.1158/1078-0432.CCR-19-3034.
MLA-Zitierstil (9. Ausg.)Sinn, Marianne, et al. "TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-generation Sequencing Results from the CONKO-001 Trial." Clinical Cancer Research, vol. 26, no. 14, 2020, https://doi.org/10.1158/1078-0432.CCR-19-3034.